Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Capital Expenditures (2016 - 2025)

Mimedx (MDXG) has disclosed Capital Expenditures for 15 consecutive years, with $285000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 8.37% to $285000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 million through Dec 2025, down 38.62% year-over-year, with the annual reading at $1.0 million for FY2025, 38.62% down from the prior year.
  • Capital Expenditures hit $285000.0 in Q4 2025 for Mimedx, up from $192000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $2.0 million in Q4 2023 to a low of -$932000.0 in Q3 2023.
  • Historically, Capital Expenditures has averaged $471750.0 across 5 years, with a median of $337000.0 in 2021.
  • Biggest YoY gain for Capital Expenditures was 436.44% in 2023; the steepest drop was 367.05% in 2023.
  • Year by year, Capital Expenditures stood at $325000.0 in 2021, then soared by 105.23% to $667000.0 in 2022, then surged by 197.9% to $2.0 million in 2023, then crashed by 86.76% to $263000.0 in 2024, then increased by 8.37% to $285000.0 in 2025.
  • Business Quant data shows Capital Expenditures for MDXG at $285000.0 in Q4 2025, $192000.0 in Q3 2025, and $179000.0 in Q2 2025.